Publications 2022

Silwal-Pandit L, Stålberg SM, Henrik J. Johansson, Georgios Mermelekas, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal D, Helland, Lingjærde OC, Labori KJ, Skålhegg BS, Janne Lehtiö, Kure EH (2022)
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Cancer Res Commun, 2 (6), 434-446
DOI 10.1158/2767-9764.CRC-21-0100, PublikaID 411

Publications 2016

Sandhu V, Lothe IMB, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Borresen-Dale AL, Lingjaerde OC, Kure EH (2016)
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
Mol. Oncol., 10 (2), 303-316
DOI 10.1016/j.molonc.2015.10.011

Sandhu V, Wedge DC, Lothe IMB, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjaerde OC, Borresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Cancer Res., 76 (17), 5092-5102
DOI 10.1158/0008-5472.CAN-16-0658

Publications 2015

Sandhu V, Lothe IMB, Labori KJ, Lingjaerde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Borresen-Dale AL, Ikdahl T, Kure EH (2015)
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
Mol. Oncol., 9 (4), 758-771
DOI 10.1016/j.molonc.2014.12.002

Publications 2012

Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing
PLoS One, 7 (4), e34150
DOI 10.1371/journal.pone.0034150

Hetland TE, Kaern J, Skrede M, Sandstad B, Trope C, Davidson B, Florenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother. Pharmacol., 69 (5), 1307-1314
DOI 10.1007/s00280-012-1835-9

Publications 2011

Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2011)
Wobble-enhanced ARMS Method for Detection of KRAS and BRAF Mutations
Diagn. Mol. Pathol., 20 (3), 158-165
DOI 10.1097/PDM.0b013e31820b49e2

Publications 2008

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Florenes VA, Kopolovic J, Reich R (2008)
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum. Pathol., 39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014

Odlo K, Hentzen J, dit Chabert JF, Ducki S, Gani OABSM, Sylte I, Skrede M, Florenes VA, Hansen TV (2008)
1,5-disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
Bioorg. Med. Chem., 16 (9), 4829-4838
DOI 10.1016/j.bmc.2008.03.049

Slipicevic A, Jorgensen K, Skrede M, Rosnes AKR, Troen G, Davidson B, Florenes VA (2008)
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276

Publications 2006

Kleinberg L, Florenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IM, Davidson B (2006)
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Virchows Arch., 449 (1), 31-39
DOI 10.1007/s00428-005-0144-7

Publications 2005

Jorgensen K, Skrede M, Cruciani W, Mikalsen SO, Slipicevic A, Florenes VA (2005)
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem. Biophys. Res. Commun., 329 (1), 266-274
DOI 10.1016/j.bbrc.2005.01.143

Schaner ME, Davidson B, Skrede M, Reich R, Florenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Trope CG, Kristensen GB, Nesland JM, Borresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol. Cancer, 4, 26
DOI 10.1186/1476-4598-4-26

Publications 2004

Florenes VA, Skrede M, Jorgensen K, Nesland JM (2004)
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Melanoma Res., 14 (3), 173-181
DOI 10.1097/01.cmr.0000129579.49313.26

Publications 2003

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Trope CG, Florenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin. Cancer Res., 9 (6), 2248-2259

Publications 1998

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dorum A, Moller P, Weber BL, Borresen-Dale AL (1998)
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum. Mutat., 11 (2), 166-174

Publications 1997

Andersen TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Eeles R, Tveit KM, Johnston SRD, Dowsett M, Olsen AO, Moller P, Stratton MR, BorresenDale AL (1997)
Screening for ESR mutations in breast and ovarian cancer patients
Hum. Mutat., 9 (6), 531-536

Publications 1996

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Florenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res., 56 (23), 5490-5498

Publications 1995

HEIMDAL K, ANDERSEN TI, SKREDE M, FOSSA SD, BERG K, BORRESEN AL (1995)
ASSOCIATION STUDIES OF ESTROGEN-RECEPTOR POLYMORPHISMS IN A NORWEGIAN TESTICULAR CANCER POPULATION
Cancer Epidemiol. Biomarkers Prev., 4 (2), 123-126

Publications 1994

ANDERSEN TI, HEIMDAL KR, SKREDE M, TVEIT K, BERG K, BORRESEN AL (1994)
ESTROGEN-RECEPTOR (ESR) POLYMORPHISMS AND BREAST-CANCER SUSCEPTIBILITY
Hum. Genet., 94 (6), 665-670

FLORENES VA, OYJORD T, HOLM R, SKREDE M, BORRESEN AL, NESLAND JM, FODSTAD O (1994)
TP53 ALLELE LOSS, MUTATIONS AND EXPRESSION IN MALIGNANT-MELANOMA
Br. J. Cancer, 69 (2), 253-259
DOI 10.1038/bjc.1994.48

Publications 1993

OTTESTAD L, ANDERSEN TI, NESLAND JM, SKREDE M, TVEIT KM, NUSTAD K, BORRESEN AL (1993)
AMPLIFICATION OF C-ERBB-2, INT-2 AND C-MYC GENES IN NODE-NEGATIVE BREAST CARCINOMAS - RELATIONSHIP TO PROGNOSIS
Acta Oncol., 32 (3), 289-294
DOI 10.3109/02841869309093597

Publications 1989

OTTESTAD L, TVEIT KM, HANNISDAL E, SKREDE M, NESLAND JM, GUNDERSEN S, PIHL A (1989)
COLONY-FORMING ABILITY OF HUMAN-BREAST CARCINOMAS - LACK OF PROGNOSTIC-SIGNIFICANCE
Br. J. Cancer, 60 (2), 216-219
DOI 10.1038/bjc.1989.254